Overview

A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of duloxetine 60 mg once daily to placebo on depression in elderly patients (greater than or equal to 65 years of age). Patients who do not respond in the first 13 weeks will be eligible for rescue using pre-defined criteria. Patients randomized to duloxetine 60 mg/day meeting the rescue criteria will be increased to 120 mg/day. Patients randomized to the placebo arm meeting the rescue criteria will be assigned to duloxetine 60 mg/day.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Boehringer Ingelheim
Treatments:
Duloxetine Hydrochloride